Donna J. Brogan Lecture in Biostatistics
This lecture honors Donna J. Brogan, an outstanding former faculty member and chair in the Department of Biostatistics at the Rollins School of Public Health. The lecture is made possiblein large part by the generous support of Donna and her colleagues and friends. Donna has been Professor Emerita since her retirement from Emory in 2004.
History of the Donna J. Brogan Lecture in Biostatistics
The Donna J. Brogan Lecture in Biostatistics was established in late 2004 by the Biostatistics Department of the Rollins School of Public Health of Emory University to honor the outstanding career of Dr. Donna Jean Brogan, a biostatistics/statistics faculty member at Emory for 34 years. Emory recognized Dr. Brogan's inspiring career with a gala retirement celebration in 2004. Her colleagues, friends and family members marked this occasion with gifts to support what would become the annual Donna J. Brogan Lecture in Biostatistics. These lectures, always in April, may be related to Dr. Brogan's research interests in sample surveys, breast cancer epidemiology and statistical education. Since the inception of the lectures in 2006, preeminent scholars and lecturers in biostatistics have visited Emory to deliver the lecture in honor of Dr. Brogan.
In 2010, Dr. Brogan made a significant contribution to establish an endowment fund that will provide funding continuity for the lecture. Her endowment, combined with generous gifts from colleagues and friends, makes possible one of only two named lectures at the Rollins School of Public Health. If you wish to contribute to the endowment fund for this lecture, click here. Please choose "Other" under Designations and enter the Donna J. Brogan Lecture in Biostatistics in the text box that appears.
2018 Donna J. Brogan Lecture
April 9, 2018 at 4:00 p.m., reception following
On Some Controversies in Cardiovascular Clinical Trials
Dr. Oakes will address some of the controversies in the design and interpretation of cardiovascular clinical trials. These include the choice of primary outcome measure, the use of composite outcome measures, and the interpretation of statistical interactions – or lack of them. The talk will be illustrated by examples from his experience in the design, conduct, and monitoring of clinical trials and of serving on FDA Advisory panels, most recently on the panel which recommended extension of the indication for liraglutide (“Victoza”), to include reduction of cardiovascular risk as well as improvement in glycemic control in patients with type 2 diabetes mellitus.